GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Edwards Lifesciences Corp (XTER:EWL) » Definitions » 3-Year Revenue Growth Rate

Edwards Lifesciences (XTER:EWL) 3-Year Revenue Growth Rate : 12.40% (As of Sep. 2024)


View and export this data going back to 1990. Start your Free Trial

What is Edwards Lifesciences 3-Year Revenue Growth Rate?

Edwards Lifesciences's Revenue per Share for the three months ended in Sep. 2024 was €2.04.

During the past 12 months, Edwards Lifesciences's average Revenue per Share Growth Rate was 25.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was 12.40% per year. During the past 5 years, the average Revenue per Share Growth Rate was 10.60% per year. During the past 10 years, the average Revenue per Share Growth Rate was 12.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Edwards Lifesciences was 15.50% per year. The lowest was -9.70% per year. And the median was 11.70% per year.

Competitive Comparison of Edwards Lifesciences's 3-Year Revenue Growth Rate

For the Medical Devices subindustry, Edwards Lifesciences's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Edwards Lifesciences's 3-Year Revenue Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Edwards Lifesciences's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Edwards Lifesciences's 3-Year Revenue Growth Rate falls into.


Edwards Lifesciences 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Edwards Lifesciences  (XTER:EWL) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Edwards Lifesciences 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Edwards Lifesciences's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Edwards Lifesciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Edwards Lifesciences Corp (XTER:EWL) » Definitions » 3-Year Revenue Growth Rate
Comparable Companies
DXCM ZBH STE PODD GMED PEN BIO MASI BRKR GKOS ABT SYK BSX MDT XTER:SHL SZSE:300760 XAMS:PHIA XSWX:SOON SHSE:688271 ASX:COH
Traded in Other Exchanges
EW:USA EW:Mexico 1EW:Italy EWL:Germany EWL:Germany E1WL34:Brazil EWLS:Austria
Address
One Edwards Way, Irvine, CA, USA, 92614
Website
https://www.edwards.com
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.